Cluster headache: state of the art in treatment.

Autor:	Rodriguez-Leyva I; Department of Neurology, Faculty of Medicine, Central Hospital 'Dr. Ignacio Morones Prieto,' Universidad Autónoma de San Luis Potosi, San Luis Potosi, Mexico., Velez-Jimenez MK; Department of Neurology, Hospital Angeles Lomas, Mexico City, Mexico., García S; Clinical Research Department, Centro Médico Nacional '20 de Noviembre,' ISSSTE, Mexico City, Mexico., Nader-Kawachi JA; Neurology and Neurosurgery Center, Médica Sur Hospital, Mexico City, Mexico., Martínez-Mayorga AP; Departament of Neurophysiology, Universidad Autónoma de San Luis Potosí, San Luis Potosi, Mexico., Melo-Carrillo A; Anesthesia Department, Critical Care, and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States., Juárez-Jimenez H; Neurology, Médica Sur Hospital, Mexico City, Mexico., Martinez-Gurrola M; Department of Neurology, General Hospital 450 Durango, Mexico City, Mexico., Gudiño-Castelazo M; Star Medica Group, Star Medica Hospital Lomas Verdes, Mexico City, Mexico., Chiquete E; Department of Neurology and Psychiatry, National Institute of Medical Science and Nutrition 'Salvador Zubirán,' Mexico City, Mexico., Villareal-Careaga J; Department of Neurology, General Hospital of Culiacan, Culiacan, Mexico., Marfil A; Headache and Chronic Pain Clinic, Neurology Service, Hospital Universitario 'Dr. J. E. González' of the Universidad Autónoma de Nuevo Leon, Monterrey, Mexico., Uribe-Jaimes PD; Neurological Center, ABC Medical Center, Mexico City, Mexico., Vargas-García RD; Department of Neurology and Psychiatry, Clínica de Merida, Merida, Mexico City, Mexico., Collado-Ortiz MA; Neurological Center, ABC Medical Center, Mexico City, Mexico., San-Juan D; Epilepsy Clinic of the National Institute of Neurology and Neurosurgery Manuel Velazco Suarez, Mexico City, Mexico.
Jazyk:	angličtina
Zdroj:	Frontiers in pain research (Lausanne, Switzerland) [Front Pain Res (Lausanne)] 2023 Oct 27; Vol. 4, pp. 1265540. Date of Electronic Publication: 2023 Oct 27 (Print Publication: 2023).
DOI:	10.3389/fpain.2023.1265540
Abstrakt:	Cluster headache (CH) is the most common and devastating autonomic headache with multiple and recent advances in treatment. However, it usually goes unrecognized and is found to have a delayed and inappropriate treatment. This paper aims to review the current therapeutic options for patients with CH. We conducted a narrative literature review on the treatments available for this condition using the American Academy of Neurology (AAN) classification of therapeutic evidence. We found effective and safe pharmacological and non-pharmacological therapies with heterogeneity of clinical trial designs for patients with CH, and they are divided into three phases, namely, transitional, acute, and preventive interventions. Prednisone (A) is the most studied treatment in the transitional phase; acute attacks are treated using triptans (A), oxygen (A), and non-invasive transcutaneous vagal nerve stimulation (A). Verapamil (A) and monoclonal antibodies (possible A) are considered the first options in preventive treatments, followed by multiple pharmacological and non-pharmacological options in prophylactic treatments. In conclusion, numerous effective and safe treatments are available in treating patients with episodic, chronic, and pharmacoresistant CH according to the clinical profile of each patient. Competing Interests: IR-L received honoraria for consulting activities, serving on advisory boards, and as a speaker from Allergan-AbbVie, Pfizer, Eli Lilly, and Carnot de México. MKV received honoraria from Allergan-AbbVie, Pfizer, Eli Lilly, Abbot, and Carnot de México. SG received honoraria for consulting activities, serving on advisory boards, and as a speaker from Eli Lilly. JAN received honoraria for consulting activities, serving on advisory boards, and as a speaker from Eli Lilly and Pfizer. AMM received honoraria for consulting activities, serving on advisory boards, and as a speaker from Pfizer. HJJ received honoraria for consulting activities, serving on advisory boards, and as a speaker from Allergan-AbbVie. MMG received honoraria for consulting activities, serving on advisory boards, and as a speaker from Pfizer. MGC received honoraria for consulting activities, serving on advisory boards, and as a speaker from Allergan-AbbVie, Grünenthal, Eli Lilly, and Pfizer. ECA received honoraria for consulting activities and serving on advisory boards and as a speaker from Novartis, Sanofi, Ferrer, Pfizer, Boehringer-Ingelheim, Merk, Silanes, ApoPharma, Asofarma, CSL, Behring, Carnot, and Ferrer Grupo. JVC received honoraria for consulting activities, serving on advisory boards, and as a speaker from Pfizer. AM received honoraria for consulting activities, serving on advisory boards, and as a speaker from Pfizer and Eli Lilly. RDV received honoraria for consulting activities, serving on advisory boards, and as a speaker from Pfizer. DSJ received honoraria for consulting activities, serving on advisory boards, and as a speaker from Pfizer. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (© 2023 Rodriguez-Leyva, Velez-Jimenez, García, Nader-Kawachi, Martínez-Mayorga, Melo-Carrillo, Juárez-Jimenez, Martinez-Gurrola, Gudiño-Castelazo, Chiquete, Villareal-Careaga, Marfil, Uribe-Jaimes, Vargas-García, Collado-Ortiz and San-Juan.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu